Alcohol-induced application site erythma after topical immunomodulator use and its inhibition by aspirin

Archives of Dermatology

Volumn 140, Issue 8, 2004, Pages 1014-1015

  Ehst, Benjamin D ^b   Warshaw, Erin M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; IMMUNOMODULATING AGENT; PIMECROLIMUS; TACROLIMUS;

ALCOHOL CONSUMPTION; BURNING SENSATION; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHEMA; HOT FLUSH; HUMAN; NOTE; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ERYTHEMA; FACIAL DERMATOSES; FEMALE; HUMANS; TACROLIMUS; TREATMENT OUTCOME; WINE;

EID: 4043120551     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.8.1014     Document Type: Note

References (5)

1. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs. 2002;62:817-840.
2. Bergman J, Rico MJ. Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg. 2001;20:250-259.
3. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000;136:999-1006.
4. Eriksson CJ. The role of acetaldehyde in the actions of alcohol (update 2000). Alcohol Clin Exp Res. 2001;25 (5, suppl ISBRA): 15S-32S.
5. Fisher AA. Four flushers: topical agents producing facial flushing simulating the systemic variety. Cutis. 1993;51:225-227.